CN1323159A - 保存血红蛋白血液替代品的方法 - Google Patents
保存血红蛋白血液替代品的方法 Download PDFInfo
- Publication number
- CN1323159A CN1323159A CN99812070A CN99812070A CN1323159A CN 1323159 A CN1323159 A CN 1323159A CN 99812070 A CN99812070 A CN 99812070A CN 99812070 A CN99812070 A CN 99812070A CN 1323159 A CN1323159 A CN 1323159A
- Authority
- CN
- China
- Prior art keywords
- blood substitute
- solution
- blood
- oxygen
- deoxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003633 blood substitute Substances 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 78
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 33
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 33
- 239000001301 oxygen Substances 0.000 claims abstract description 102
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 102
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 96
- 230000004888 barrier function Effects 0.000 claims abstract description 45
- 229920000642 polymer Polymers 0.000 claims description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 claims description 19
- 108010002255 deoxyhemoglobin Proteins 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 238000004321 preservation Methods 0.000 claims description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 10
- 230000008595 infiltration Effects 0.000 claims description 9
- 238000001764 infiltration Methods 0.000 claims description 9
- 239000004715 ethylene vinyl alcohol Substances 0.000 claims description 7
- 229920001179 medium density polyethylene Polymers 0.000 claims description 7
- 239000004701 medium-density polyethylene Substances 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 229920000728 polyester Polymers 0.000 claims description 7
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 claims description 6
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 claims description 6
- 229920000092 linear low density polyethylene Polymers 0.000 claims description 6
- 239000004707 linear low-density polyethylene Substances 0.000 claims description 6
- 229910052786 argon Inorganic materials 0.000 claims description 5
- 239000001307 helium Substances 0.000 claims description 5
- 229910052734 helium Inorganic materials 0.000 claims description 5
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000002861 polymer material Substances 0.000 claims 4
- 230000035699 permeability Effects 0.000 abstract description 3
- 239000002648 laminated material Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 131
- 210000004369 blood Anatomy 0.000 description 77
- 239000008280 blood Substances 0.000 description 77
- 210000003743 erythrocyte Anatomy 0.000 description 62
- 239000007853 buffer solution Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 238000006116 polymerization reaction Methods 0.000 description 33
- 239000007788 liquid Substances 0.000 description 30
- -1 polyethylene Polymers 0.000 description 28
- 238000011026 diafiltration Methods 0.000 description 26
- 239000000463 material Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 238000000108 ultra-filtration Methods 0.000 description 19
- 239000008215 water for injection Substances 0.000 description 19
- 239000003431 cross linking reagent Substances 0.000 description 18
- 239000000644 isotonic solution Substances 0.000 description 18
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 17
- 239000012530 fluid Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000003068 static effect Effects 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000000502 dialysis Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 14
- 108010061951 Methemoglobin Proteins 0.000 description 12
- 238000001471 micro-filtration Methods 0.000 description 12
- 239000012279 sodium borohydride Substances 0.000 description 12
- 229910000033 sodium borohydride Inorganic materials 0.000 description 12
- 238000001914 filtration Methods 0.000 description 11
- 229920000098 polyolefin Polymers 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 239000004743 Polypropylene Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 239000011261 inert gas Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 230000035479 physiological effects, processes and functions Effects 0.000 description 8
- 229920001155 polypropylene Polymers 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000004201 L-cysteine Substances 0.000 description 7
- 125000003047 N-acetyl group Chemical group 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000003139 buffering effect Effects 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 239000003344 environmental pollutant Substances 0.000 description 7
- 238000011010 flushing procedure Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229940049954 penicillin Drugs 0.000 description 7
- 231100000719 pollutant Toxicity 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 239000004677 Nylon Substances 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 229920001778 nylon Polymers 0.000 description 6
- 229920006254 polymer film Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000011082 depyrogenation Methods 0.000 description 5
- 238000003475 lamination Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 239000012471 diafiltration solution Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- BLSAPDZWVFWUTL-UHFFFAOYSA-N 2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OS(=O)(=O)C1CC(=O)NC1=O BLSAPDZWVFWUTL-UHFFFAOYSA-N 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 229920013683 Celanese Polymers 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229920001684 low density polyethylene Polymers 0.000 description 3
- 239000004702 low-density polyethylene Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LXWLHXNRALVRSL-UHFFFAOYSA-N 3-(oxiran-2-ylmethoxy)propylsilane Chemical compound [SiH3]CCCOCC1CO1 LXWLHXNRALVRSL-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229940064734 aminobenzoate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108010036302 hemoglobin AS Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000000899 immune system response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- UFFVWIGGYXLXPC-UHFFFAOYSA-N 1-[2-(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=CC=C1N1C(=O)C=CC1=O UFFVWIGGYXLXPC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- GFGSZUNNBQXGMK-UHFFFAOYSA-N 2-chloro-4-nitrobenzamide Chemical compound NC(=O)C1=CC=C([N+]([O-])=O)C=C1Cl GFGSZUNNBQXGMK-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical class Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229910000851 Alloy steel Inorganic materials 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FXDUKPADYVGEAW-UHFFFAOYSA-K C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(CN)N.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+] Chemical compound C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(C)(=O)O.C(CN)N.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+] FXDUKPADYVGEAW-UHFFFAOYSA-K 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N alpha-mercaptoacetic acid Natural products OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108010037743 hemoglobin glutamer-200 Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910001026 inconel Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VLCAYQIMSMPEBW-UHFFFAOYSA-N methyl 3-hydroxy-2-methylidenebutanoate Chemical compound COC(=O)C(=C)C(C)O VLCAYQIMSMPEBW-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0263—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
参数 | 结果 |
PH(18-22℃) | 生理可接受的 |
内毒素 | 生理可接受的 |
无菌测试 | 满足测试 |
磷脂a | 生理可接受的 |
总血红蛋白高铁血红蛋白氧基血红蛋白 | 10-250克/升<15%<10% |
钠Na+钾K+氯Cl-钙Ca++硼 | 生理可接受的 |
戊二醛 | 生理可接受的 |
N-乙酰基-L-半胱氨酸 | 生理可接受的 |
M.W.>500,000 | ≤15% |
M.W.≤65,000 | <10% |
M.W.<32,000 | <5% |
微粒含量>10μ | <12/毫升 |
微粒含量>25μ | <2/毫升 |
月数 | NAC | NAC2 | THb | HbO2 | metHb |
0 | 0.18 | 0.01 | 12.4 | 3 | 1 |
3 | 0.03 | 0.21 | 12.0 | 3 | 6 |
规格 | ≤0.24 | ≤0.24 | 12.0-14.0 | ≤10 | ≤15 |
参数 | 结果 |
PH(18-22℃) | 生理可接受的 |
内毒素 | <0.5EU/毫升 |
无菌测试 | 满足测试 |
磷脂 a | <0.3nm/毫升 |
总血红蛋白高铁血红蛋白氧基血红蛋白 | 12.0-14.0克/dl<15%<10% |
钠Na+钾K+氯Cl-钙Ca++硼 | 146-160mM3.5-5.5mM105-120mM0.5-1.5mM<10ppm |
等渗容摩 | 290-310mOsm |
戊二醛 | <3.5毫微克/毫升 |
N-乙酰基-L-半胱氨酸 | <0.2% |
M.W.>500,000 | <15% |
未修饰四聚体 | <5% |
微粒含量>10μ | <12/毫升 |
微粒含量>25μ | <2/毫升 |
参数 | 结果 |
PH(18-22℃) | 生理可接受的 |
内毒素 | <0.5EU/毫升 |
无菌测试 | 满足测试 |
磷脂 a | <0.3nm/毫升 |
总血红蛋白高铁血红蛋白氧基血红蛋白 | 12.0-14.0克/dl<15%<10% |
钠Na+钾K+氯Cl-钙Ca++硼 | 146-160mM3.5-5.5mM105-120mM0.5-1.5mM<10ppm |
等渗容摩 | 290-310mOsm |
戊二醛 | <3.5毫微克/毫升 |
N-乙酰基-L-半胱氨酸 | ≤0.2% |
M.W.>500,000 | ≤15% |
M.W.≤65,000 | <10% |
M.W.>32,000 | <5% |
微粒含量>10μ | <12/毫升 |
微粒含量>25μ | <2/毫升 |
Claims (20)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/173,189 | 1998-10-14 | ||
US09/173,189 US6271351B1 (en) | 1995-03-23 | 1998-10-14 | Method for preserving a hemoglobin blood substitute |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1323159A true CN1323159A (zh) | 2001-11-21 |
CN1233230C CN1233230C (zh) | 2005-12-28 |
Family
ID=22630898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998120707A Expired - Fee Related CN1233230C (zh) | 1998-10-14 | 1999-10-13 | 保存血红蛋白血液替代品的方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6271351B1 (zh) |
EP (1) | EP1121016B1 (zh) |
JP (1) | JP4674358B2 (zh) |
CN (1) | CN1233230C (zh) |
AT (1) | ATE230924T1 (zh) |
AU (1) | AU743248B2 (zh) |
CA (1) | CA2346466A1 (zh) |
DE (1) | DE69904960T2 (zh) |
DK (1) | DK1121016T3 (zh) |
ES (1) | ES2186418T3 (zh) |
HK (1) | HK1041415B (zh) |
NZ (1) | NZ511008A (zh) |
TW (1) | TWI235662B (zh) |
WO (1) | WO2000021366A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104105705A (zh) * | 2010-12-08 | 2014-10-15 | 波士顿治疗公司 | 血红蛋白组合物及其使用方法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610832B1 (en) * | 1995-03-23 | 2003-08-26 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
US6518010B2 (en) | 2001-02-28 | 2003-02-11 | Biopure Corporation | Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier |
DE60234142D1 (de) * | 2001-03-27 | 2009-12-10 | Nipro Corp | Albuminlösung enthaltender Kunststoffbehälter |
US6974447B2 (en) | 2001-04-17 | 2005-12-13 | Baxter International Inc. | High gas barrier receptacle and closure assembly |
AU2002254646B2 (en) * | 2001-04-18 | 2008-05-15 | Northfield Laboratories, Inc. | Flexible container system for storage of stabilized hemoglobin solutions |
CA2348042A1 (en) | 2001-06-04 | 2002-12-04 | Ann Huletsky | Sequences for detection and identification of methicillin-resistant staphylococcus aureus |
US7001715B2 (en) | 2002-02-28 | 2006-02-21 | Biopure Corporation | Purification of red blood cells by separation and diafiltration |
CN1703235A (zh) * | 2002-10-03 | 2005-11-30 | 北原实验室有限公司 | 治疗大量失血患者的方法 |
EP1592437A4 (en) * | 2003-01-29 | 2007-12-26 | Northfield Lab | POLYMERIZED HEMOGLOBIN SOLUTIONS WITH REDUCED TETRAMER QUANTITY AND MANUFACTURING METHOD |
BRPI0414321B8 (pt) | 2003-09-22 | 2021-06-22 | Baxter Healthcare Sa | esterilização à alta pressão para esterilização final de preparações farmacêuticas e produtos médicos |
US7135554B1 (en) | 2004-01-27 | 2006-11-14 | Biopure Corporation | Method of forming a polymerized hemoglobin solution from stabilized hemoglobin |
JP2006164312A (ja) * | 2004-12-02 | 2006-06-22 | Hitachi Ltd | 半導体装置およびそれを用いた磁気記録再生装置 |
US11834720B2 (en) | 2005-10-11 | 2023-12-05 | Geneohm Sciences, Inc. | Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx |
US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
JP2009524436A (ja) * | 2006-01-24 | 2009-07-02 | ノースフィールド ラボラトリーズ、インコーポレイテッド | 重合したヘモグロビンの培地、並びに島細胞の単離及び移植におけるその使用 |
EP2118311B1 (en) * | 2006-12-19 | 2013-07-03 | GeneOhm Sciences, Inc. | Detection of staphylococcus aureus and identification of methicillin-resistant staphylococcus aureus |
US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
PT2440239T (pt) | 2009-06-09 | 2017-10-19 | Prolong Pharmaceuticals Llc | Composições de hemoglobina |
US20140004022A1 (en) * | 2009-07-02 | 2014-01-02 | Sio2 Medical Products, Inc. | Pecvd coating of chromatography vials |
US20110319858A1 (en) * | 2010-06-23 | 2011-12-29 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical compositions and the use thereof |
CN103251998B (zh) * | 2012-11-08 | 2015-09-02 | 亿京国际有限公司 | 用于血红蛋白氧载体(hboc)溶液的精确输注递送系统 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE416194C (de) | 1923-02-05 | 1925-07-11 | Gaston De Dudzeele | Verfahren zum Strecken, Walzen und Ziehen von Metallen |
US4061736A (en) | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
US4001401A (en) | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
US4001200A (en) | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
US4053590A (en) | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
DE7621615U1 (de) | 1976-07-08 | 1977-02-03 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Beutel zur aufnahme von blut und blutbestandteilen |
US4140162A (en) | 1977-07-28 | 1979-02-20 | Baxter Travenol Lab | Clear, autoclavable plastic formulation free of liquid plasticizers |
IT1205425B (it) | 1980-10-14 | 1989-03-23 | Andrea Venturini | Impianto di catalizzazione della combustione di combustibili commerciali |
DE3277609D1 (en) | 1982-01-07 | 1987-12-17 | Fresenius Ag | Preservation bag |
US4704402A (en) | 1982-06-12 | 1987-11-03 | University Of Pittsburgh | Method of treating sickle cell anemia |
JPS5967A (ja) * | 1982-06-25 | 1984-01-05 | 積水化学工業株式会社 | 医療器材用樹脂組成物 |
IT1181945B (it) * | 1984-12-31 | 1987-09-30 | Manuli Autoadesivi Spa | Perfezionamento nei nastri autoadesivi |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5194590A (en) | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US4826811A (en) | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US5084558A (en) | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
GB8710598D0 (en) | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
US5189146A (en) | 1987-05-05 | 1993-02-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Pasteurizable, freeze-driable hemoglobin-based blood substitute |
US4826955A (en) * | 1988-01-21 | 1989-05-02 | Allied-Signal Inc. | Amorphous copolyamide article of manufacture with moisture-insensitive oxygen barrier properties |
US4988515A (en) | 1988-01-28 | 1991-01-29 | The Regents Of The Univ. Of Calif. | Cardioplegic solution |
US4861867A (en) | 1988-02-03 | 1989-08-29 | Baxter International, Inc. | Purified hemoglobin solutions and method for making same |
US5178884A (en) | 1988-05-18 | 1993-01-12 | Cryopharm Corporation | Lyophilized and reconstituted red blood cell compositions |
JP2592973B2 (ja) | 1988-06-15 | 1997-03-19 | バクスター インターナショナル インコーポレーテッド | 架橋ヘモグロビンの精製方法 |
US5051353A (en) | 1988-08-09 | 1991-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Preservation and restoration of hemoglobin in blood substitutes |
US5100401A (en) | 1988-11-14 | 1992-03-31 | Baxter International Inc. | Plastic composition with anti-hemolytic effect |
US5167657A (en) | 1988-11-14 | 1992-12-01 | Baxter International Inc. | Plastic composition with anti-hemolytic effect |
US5045529A (en) | 1989-03-27 | 1991-09-03 | Bionostics, Inc. | Tonometric fluid for blood gas and co-oximetry instruments |
JP2716514B2 (ja) * | 1989-03-31 | 1998-02-18 | 住友ベークライト株式会社 | 積層体 |
DE3915252A1 (de) | 1989-05-10 | 1990-11-15 | Fresenius Ag | Transparenter, flexibler beutel aus thermoplastischem kunststoff fuer die lagerung von thrombozytenkonzentraten |
US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
US5439882A (en) | 1989-12-29 | 1995-08-08 | Texas Tech University Health Sciences Center | Blood substitute |
US5352773A (en) | 1990-08-06 | 1994-10-04 | Baxter International Inc. | Stable hemoglobin based composition and method to store same |
JP2963753B2 (ja) * | 1990-09-27 | 1999-10-18 | 三菱化学株式会社 | 医療用プラスチックバッグの製造方法 |
US5334706A (en) | 1992-01-30 | 1994-08-02 | Baxter International | Administration of low dose hemoglobin to increase perfusion |
US5296466A (en) | 1992-02-19 | 1994-03-22 | Board Of Regents, The University Of Texas System | Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
US5356709A (en) | 1992-05-14 | 1994-10-18 | Baxter International, Inc. | Non-PVC coextruded medical grade port tubing |
US5264555A (en) | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
JPH07100185A (ja) * | 1993-10-06 | 1995-04-18 | Terumo Corp | 医薬液入り容器 |
US5683768A (en) | 1994-12-21 | 1997-11-04 | Baxter International Inc. | Plastic formulations for platelet storage containers and the like |
CA2215697C (en) * | 1995-03-23 | 2009-08-18 | Biopure Corporation | Stable polymerized hemoglobin blood-substitute |
US5691452A (en) * | 1995-03-23 | 1997-11-25 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
US5929031A (en) | 1995-05-02 | 1999-07-27 | Baxter Biotech Technology Sarl | Storage stable hemoglobin solutions |
AU1716697A (en) | 1996-03-21 | 1997-10-10 | Sengewald Verpackungen Gmbh | Multilayered sheet, process for the production thereof and use thereof |
-
1998
- 1998-10-14 US US09/173,189 patent/US6271351B1/en not_active Expired - Fee Related
-
1999
- 1999-10-13 CA CA002346466A patent/CA2346466A1/en not_active Abandoned
- 1999-10-13 WO PCT/US1999/023631 patent/WO2000021366A1/en active IP Right Grant
- 1999-10-13 JP JP2000575363A patent/JP4674358B2/ja not_active Expired - Fee Related
- 1999-10-13 DE DE69904960T patent/DE69904960T2/de not_active Expired - Lifetime
- 1999-10-13 NZ NZ511008A patent/NZ511008A/xx not_active IP Right Cessation
- 1999-10-13 EP EP99951910A patent/EP1121016B1/en not_active Expired - Lifetime
- 1999-10-13 CN CNB998120707A patent/CN1233230C/zh not_active Expired - Fee Related
- 1999-10-13 ES ES99951910T patent/ES2186418T3/es not_active Expired - Lifetime
- 1999-10-13 AT AT99951910T patent/ATE230924T1/de not_active IP Right Cessation
- 1999-10-13 AU AU64249/99A patent/AU743248B2/en not_active Ceased
- 1999-10-13 DK DK99951910T patent/DK1121016T3/da active
- 1999-10-14 TW TW088117769A patent/TWI235662B/zh not_active IP Right Cessation
-
2002
- 2002-04-02 HK HK02102444.6A patent/HK1041415B/zh not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104105705A (zh) * | 2010-12-08 | 2014-10-15 | 波士顿治疗公司 | 血红蛋白组合物及其使用方法 |
CN104105705B (zh) * | 2010-12-08 | 2017-05-31 | 波士顿治疗公司 | 血红蛋白组合物及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69904960T2 (de) | 2004-01-29 |
US6271351B1 (en) | 2001-08-07 |
HK1041415B (zh) | 2006-08-04 |
AU743248B2 (en) | 2002-01-24 |
CN1233230C (zh) | 2005-12-28 |
AU6424999A (en) | 2000-05-01 |
DE69904960D1 (de) | 2003-02-20 |
WO2000021366A1 (en) | 2000-04-20 |
TWI235662B (en) | 2005-07-11 |
ATE230924T1 (de) | 2003-02-15 |
EP1121016B1 (en) | 2003-01-15 |
JP4674358B2 (ja) | 2011-04-20 |
NZ511008A (en) | 2003-02-28 |
DK1121016T3 (da) | 2003-02-24 |
ES2186418T3 (es) | 2003-05-01 |
HK1041415A1 (en) | 2002-07-12 |
CA2346466A1 (en) | 2000-04-20 |
JP2002527360A (ja) | 2002-08-27 |
EP1121016A1 (en) | 2001-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1191754C (zh) | 用透明外包装保存血红蛋白血液代用品 | |
CN1256076C (zh) | 用氧屏障膜外包装保存血红蛋白血液代用品的方法及其产品 | |
CN1233230C (zh) | 保存血红蛋白血液替代品的方法 | |
US5895810A (en) | Stable polymerized hemoglobin and use thereof | |
EP0832130B1 (en) | Separating polymerized from unpolymerized hemoglobin using hydroxyapatite | |
US5753616A (en) | Method for producing a stable polymerized hemoglobin blood-substitute | |
CN1166689C (zh) | 血红蛋白的纯化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: OPK BIOTECHNOLOGY LLC Free format text: FORMER OWNER: BIOPURE CORP Effective date: 20100629 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100629 Address after: Massachusetts, USA Patentee after: OPK Biological Technology Co., Ltd. Address before: Massachusetts, USA Patentee before: Biopure Corp. |
|
ASS | Succession or assignment of patent right |
Owner name: HEMOGLOBIN OXYGEN THERAPY LLC Free format text: FORMER OWNER: OPK BIOTECH LLC Effective date: 20150327 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150327 Address after: American Pennsylvania Patentee after: Hemoglobin oxygen therapy Co Ltd Address before: Massachusetts, USA Patentee before: OPK Biological Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051228 Termination date: 20161013 |
|
CF01 | Termination of patent right due to non-payment of annual fee |